$CTSO News

WBB Securities Initiates Coverage On CytoSorbents with Speculative Buy Rating, Announces Price Target of $9.5

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents Regains Nasdaq Compliance

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CytoSorbents Announces Reverse Stock Split

CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor

Cytosorbents Announces 1-for-20 Reverse Stock Split, Effective September 8

CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents Corporation 2026 Q2 - Results - Earnings Call Presentation

Cytosorbents Corporation Q2 2026 Earnings Call Summary

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ...

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA

Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026